Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus.

Naik H, Lu J, Cao C, Pfister M, Vakilynejad M, Leifke E.

CPT Pharmacometrics Syst Pharmacol. 2013 Jan 9;2:e22. doi: 10.1038/psp.2012.23.

2.

Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes.

Kaku K, Araki T, Yoshinaka R.

Diabetes Care. 2013 Feb;36(2):245-50. doi: 10.2337/dc12-0872. Epub 2012 Oct 18.

3.

GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.

Araki T, Hirayama M, Hiroi S, Kaku K.

Diabetes Obes Metab. 2012 Mar;14(3):271-8. doi: 10.1111/j.1463-1326.2011.01525.x. Epub 2011 Dec 22.

PMID:
22051148
4.

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.

Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N, Takeuchi K.

Br J Pharmacol. 2013 Oct;170(3):568-80. doi: 10.1111/bph.12297.

5.

A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.

Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, Vakilynejad M.

Clin Pharmacol Ther. 2012 Jul;92(1):29-39. doi: 10.1038/clpt.2012.43. Epub 2012 Jun 6.

PMID:
22669289
6.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
7.

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K, Morita K, Inukai T.

Transl Res. 2012 Jan;159(1):25-31. doi: 10.1016/j.trsl.2011.09.005. Epub 2011 Oct 17.

PMID:
22153807
8.

High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.

Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, Lane W, Ivetac A, Aertgeerts K, Nguyen J, Jennings A, Okada K.

Nature. 2014 Sep 4;513(7516):124-7. doi: 10.1038/nature13494. Epub 2014 Jul 20.

PMID:
25043059
9.

Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.

Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, Leifke E.

J Clin Pharmacol. 2012 Jul;52(7):1007-16. doi: 10.1177/0091270011409230. Epub 2011 May 24.

PMID:
21610201
10.

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs MA.

J Clin Pharmacol. 2012 Oct;52(10):1494-505. Epub 2011 Dec 12.

PMID:
22162539
11.
12.

Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Kadowaki T, Kondo K.

Diabetes Obes Metab. 2013 Sep;15(9):810-8. doi: 10.1111/dom.12092. Epub 2013 Apr 7.

PMID:
23464664
13.

TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.

Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K.

J Pharmacol Exp Ther. 2011 Oct;339(1):228-37. doi: 10.1124/jpet.111.183772. Epub 2011 Jul 13.

14.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2.

PMID:
21723606
15.

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.

Hollander PA, Kushner P.

Postgrad Med. 2010 May;122(3):71-80. doi: 10.3810/pgm.2010.05.2144.

PMID:
20463416
16.
17.

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.

Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.

PMID:
20637971
18.

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments.

Møller JB, Overgaard RV, Kjellsson MC, Kristensen NR, Klim S, Ingwersen SH, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2013 Oct 30;2:e82. doi: 10.1038/psp.2013.58.

19.

Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.

Ndefo UA, Okoli O, Erowele G.

Am J Health Syst Pharm. 2014 Jan 15;71(2):103-9. doi: 10.2146/ajhp130131. Review.

PMID:
24375601
20.

Comparisons of Analysis Methods for Proof-of-Concept Trials.

Karlsson KE, Vong C, Bergstrand M, Jonsson EN, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2013 Jan 16;2:e23. doi: 10.1038/psp.2012.24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk